In recent years, brain diseases have seriously threatened human health due to their high
morbidity and mortality. Achieving efficient drug delivery to provide satisfactory therapeutic …

Thrombosis is a principle cause of various life-threatening cardiovascular diseases.
However, current antithrombotic treatments using drugs only offer limited efficacy due to …

Rational design of nanomedicine to accelerate thrombolysis and sequentially avoid
thrombolysis-mediated reperfusion injury is still a challenge. Here, we develop a biomimetic …

Sowing malignant cells (the “seeds” of metastasis) to engraft secondary sites requires a
conducive premetastatic niche (PMN, the “soil” of metastasis). Inflammation and tumor …

Thrombotic occlusions of blood vessels are responsible for life-threatening cardiovascular
disorders such as myocardial infarction, ischemic stroke, and venous thromboembolism …

Antithrombosis therapy is confronted with short half-lives of thrombolytic agents, limited
therapeutic effects, and bleeding complications. Drug delivery systems of thrombolytic …

Ischemic stroke is a vascular central nervous system (CNS) disease that leads a disability
and death. Thrombolysis and neuroprotection are the primary treatment strategies of …

Smart drug delivery systems represent state-of-the-art approaches for targeted therapy of life-
threatening diseases such as cancer and cardiovascular diseases. Stimuli-responsive on …

Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …

In thrombotic diseases, the effects of reactive oxygen species (ROS)‐mediated oxidative
stress as a “perpetrator” in thrombosis must be resolved. Accordingly, an insufficient …